Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial. Issue 3 (June 2016)

• Record Type: Journal Article
• Authors: Ursoniu, Sorin; Sahebkar, Amirhossein; Andrica, Florina; Serban, Corina; Banach, Maciej
• Is Part Of: Clinical nutrition. Volume 35:Issue 3(2016:Jun.)
• Page Start: 615
• Page End: 625
• Publication Date: 2016-06
• Subjects: Flaxseed -- Linum usitatissimum -- Arterial hypertension -- Meta-analysis -- Systematic review; Critically ill -- Nutrition -- Periodicals; Diet therapy -- Periodicals; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; Enteral Nutrition -- Periodicals; Parenteral Nutrition -- Periodicals; Metabolism -- Periodicals; Diétothérapie -- Périodiques; Alimentation parentérale -- Périodiques; Alimentation entérale -- Périodiques; Nutrition -- Périodiques; Diet therapy; Enteral feeding; Nutrition; Parenteral feeding; Electronic journals; Periodicals; Electronic journals; 615.854
• DOI: 10.1016/j.clnu.2015.05.012
• Languages: English
• ISSNs: 0261-5614

Abstract

Summary: Background & aims: Many experimental and clinical trials suggested that flaxseed might be a potent antihypertensive, but the evidences concerning the effects of flaxseed supplements on blood pressure (BP) has not been fully conclusive. We aimed to assess the impact of the effects of flaxseed supplements on blood pressure through systematic review of literature and meta-analysis of available randomized controlled trials (RCTs). Methods: The literature search included PUBMED, Cochrane Library, Scopus, and EMBASE up to February 2015 to identify RCTs investigating the effect of flaxseed supplements on plasma blood pressure. Effect size was expressed as weighed mean difference (WMD) and 95% confidence interval (CI). Results: 15 trials (comprising 19 treatment arms) with 1302 participants were included in this meta-analysis. Random-effects meta-analysis suggested significant reductions in both systolic BP (SBP) (WMD: −2.85 mmHg, 95%CI: −5.37 to −0.33, p = 0.027) and diastolic BP (DBP) (WMD: −2.39 mmHg, 95%CI: −3.78 to −0.99, p = 0.001) following supplementation with flaxseed products. When the studies were stratified according to their duration, there was a greater effect on both SBP and DBP in the subset of trials with ≥12 weeks of duration (WMD: −3.10 mmHg, 95%CI: −6.46 to 0.27, p = 0.072 and −2.62 mmHg, 95%CI: −4.39 to −0.86, p = 0.003, respectively) vs the subset lasting <12 weeks (WMD: −1.60 mmHg, 95%CI: −5.44 to 2.24, p = 0.413, and −1.74 mmHg, 95%CI: −4.41 to 0.93, p = 0.202, respectively). Another subgroup analysis was performed to assess the impact of flaxseed supplement type on BP. Reduction of SBP was significant with flaxseed powder (WMD: −1.81 mmHg, 95% CI: −2.03 to −1.59, p < 0.001) but not oil (WMD: −4.62 mmHg, 95%CI: −11.86 to 2.62, p = 0.211) and lignan extract (WMD: 0.28 mmHg, 95% CI: −3.49 to 4.04, p = 0.885). However, DBP was significantly reduced with powder and oil preparations (WMD: −1.28 mmHg, 95% CI: −2.44 to −0.11, p = 0.031, and −4.10 mmHg, 95%CI: −6.81 to −1.39, p = 0.003, respectively), but not with lignan extract (WMD: −1.78 mmHg, 95% CI: −4.28 to 0.72, p = 0.162). Conclusions: This meta-analysis of RCTs showed significant reductions in both SBP and DBP following supplementation with various flaxseed products.